No­var­tis her­alds a PhI­II suc­cess for sec­ondary pro­gres­sive MS drug

No­var­tis has scored a suc­cess for a Phase III study of BAF312 (sipon­i­mod), re­duc­ing the risk of crip­pling CNS dam­age in sec­ondary pro­gres­sive mul­ti­ple scle­ro­sis. The drug is in a class of S1P re­cep­tor mod­u­la­tors that has at­tract­ed con­sid­er­able at­ten­tion in the field.

In­ves­ti­ga­tors set out to see if the drug could hit its pri­ma­ry end­point: re­duc­ing the risk of three-month con­firmed dis­abil­i­ty pro­gres­sion ver­sus place­bo. In sec­ondary pro­gres­sive MS pa­tients con­tin­ue to wors­en in­de­pen­dent of the pe­ri­od­ic flare ups that af­flict pa­tients with re­laps­ing-re­mit­ting MS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.